These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36258065)

  • 21. Lusutrombopag: First Global Approval.
    Kim ES
    Drugs; 2016 Jan; 76(1):155-8. PubMed ID: 26666417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment.
    Sato S; Miyake T; Kataoka M; Isoda K; Yazaki T; Tobita H; Ishimura N; Kinoshita Y
    Intern Med; 2017 Nov; 56(21):2887-2890. PubMed ID: 28943563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching.
    Furuichi Y; Takeuchi H; Yoshimasu Y; Kasai Y; Abe M; Itoi T
    Hepatol Res; 2020 Sep; 50(9):1062-1070. PubMed ID: 32510789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is platelet monitoring during 7-day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase IIIb open-label study.
    Numata K; Tanaka K; Katsube T; Ochiai T; Fukuhara T; Kano T; Osaki Y; Izumi N; Imawari M
    Hepatol Res; 2020 Oct; 50(10):1141-1150. PubMed ID: 32609920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance.
    Sasaki R; Shiino C; Imawari M; Bentley R; Cai B; Yoshida M; Afdhal N
    Hepatol Res; 2019 Oct; 49(10):1169-1181. PubMed ID: 31228221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia.
    Tsuji Y; Kawaratani H; Ishida K; Kaya D; Kubo T; Fujinaga Y; Sawada Y; Takaya H; Shimozato N; Kaji K; Namisaki T; Moriya K; Akahane T; Yoshiji H
    Dig Dis; 2020; 38(4):329-334. PubMed ID: 31655803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.
    Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Tanaka T; Sunago K; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Abe M; Joko K; Michitaka K; Hiasa Y
    J Gastroenterol Hepatol; 2020 Feb; 35(2):299-304. PubMed ID: 31318996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia.
    Ishikawa T; Okoshi M; Tomiyoshi K; Kojima Y; Horigome R; Imai M; Nozawa Y; Iwanaga A; Sano T; Honma T; Yoshida T
    Hepatol Res; 2019 May; 49(5):590-593. PubMed ID: 30602063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between response to lusutrombopag and splenic volume.
    Uojima H; Arase Y; Itokawa N; Atsukawa M; Satoh T; Miyazaki K; Hidaka H; Sung JH; Kako M; Tsuruya K; Kagawa T; Iwakiri K; Horie R; Koizumi W
    World J Gastroenterol; 2018 Dec; 24(46):5271-5279. PubMed ID: 30581275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.
    Wada N; Uojima H; Satoh T; Okina S; Iwasaki S; Shao X; Takiguchi H; Arase Y; Itokawa N; Atsukawa M; Miyazaki K; Hidaka H; Kako M; Kagawa T; Iwakiri K; Horie R; Suzuki T; Koizumi W
    Dig Dis; 2021; 39(3):234-242. PubMed ID: 32759604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.
    Terrault NA; Hassanein T; Howell CD; Joshi S; Lake J; Sher L; Vargas H; McIntosh J; Tang S; Jenkins TM
    J Hepatol; 2014 Dec; 61(6):1253-9. PubMed ID: 25048952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States.
    Dieterich DT; Bernstein D; Flamm S; Pockros PJ; Reau N
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1311-1322. PubMed ID: 32813292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center study.
    Kawaratani H; Tsuji Y; Ishida K; Kaya D; Kubo T; Fujinaga Y; Sawada Y; Sato S; Takaya H; Kaji K; Namisaki T; Moriya K; Akahane T; Yoshiji H
    Hepatol Res; 2020 Sep; 50(9):1101-1105. PubMed ID: 32558192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Avatrombopag: A Review in Thrombocytopenia.
    Markham A
    Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients - a phase II randomized controlled clinical trial.
    Chakraborty S; Alam S; Sayem M; Sanyal M; Das T; Saha P; Sayem M; Byapari BK; Tabassum CT; Kabir A; Amin MR; Nabi AHMN
    EClinicalMedicine; 2020 Dec; 29-30():100624. PubMed ID: 33294822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
    Khemichian S; Terrault NA
    Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lusutrombopag as a substitute for platelet transfusion for thrombocytopenia associated with chronic liver disease in a patient undergoing endoscopic spinal surgery: A case report.
    Kaneko T; Takano Y; Ishibashi K
    Medicine (Baltimore); 2021 Jan; 100(2):e24094. PubMed ID: 33466174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lusutrombopag has slightly stronger effects on patients with mild thrombocytopenia compared with those with severe thrombocytopenia: A multicenter propensity score matching study.
    Furuichi Y; Takeuchi H; Uojima H; Atsukawa M; Arai T; Arase Y; Kako M; Hidaka H; Itoi T
    J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):439-448. PubMed ID: 34953107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
    Xu H; Cai R
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.